Companies › Traws Pharma
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TRX-100 CEN inhibitor | – | Phase 2 | Influenza; Healthy Volunteer | Dec 2026 |
| Ratutrelvir (83-0060) Covalent inhibitor of SARS-CoV-2 main protease (Mpro; 3CL) | – | Phase 2 | COVID - 19 | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07157007 | Ratutrelvir (83-0060) | Phase 2 | COVID - 19 | Infectious disease | Feb 2026 |
| NCT07371650 | TRX-100 | Phase 2 | Influenza | Infectious disease | Dec 2026 |
| NCT07526506 | TRX-100 | Phase 1 | Healthy Volunteer | Infectious disease | Feb 2027 |
Cash of $5m on 2026-06-30; operating cash outflow about $20m a year; runway about 3 months at that burn, to Sep 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
60 Degrees Pharmaceuticals Lakewood-Amedex Acurx Pharmaceuticals Amplexd Therapeutics Sano Chemicals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.